SCHEMBL973284

SCHEMBL973284

CN=C(N)NCc1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.50
▸ HTT P42858 2/20 0.49
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ RCE1 Q9Y256 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HTR3E A5X5Y0 1/20 0.45
▸ HTR3B O95264 1/20 0.45
▸ HTR3A P46098 1/20 0.45
▸ HTR3D Q70Z44 1/20 0.45
▸ HTR3C Q8WXA8 1/20 0.45
▸ ANPEP P15144 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9271452 0.80 NPC1 (0.53) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL9271447 0.80 NPC1 (0.53) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL4681736 0.79 NPC1 (0.51) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL4681732 0.79 NPC1 (0.51) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL973274 0.78 NPC1 (0.54) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL8954327 0.77 NPC1 (0.61) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL625881 0.77 NPC1 (0.72) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL4023664 0.77 NPC1 (0.61) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL2781731 0.73 ADRA2A (0.54) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL13810448 0.73 NPC1 (0.61) NPC1RAB9AALDH1A1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009446-A1 OLIGOMER-GUANIDINE CLASS CONJUGATES NEKTAR THERAPEUTICS (US) 2011-01-13 — — US claimed
WO-2009089053-A1 OLIGOMER-GUANIDINE CLASS CONJUGATES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-07-16 — — WO claimed
US-20110009446-A1 OLIGOMER-GUANIDINE CLASS CONJUGATES NEKTAR THERAPEUTICS (US) 2011-01-13 — — US disclosed
WO-2009089053-A1 OLIGOMER-GUANIDINE CLASS CONJUGATES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009446-A1 OLIGOMER-GUANIDINE CLASS CONJUGATES GMPS, OGT, GBA1 NPC1 162/4885RAB9A 1112/4885ALDH1A1 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback